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ABSTRACT 
 Heart failure remains a global burden despite important progress that has been made 
in the management of heart failure. Guidelines from ESC and AHA are still widely used as a 
guidance for diagnosis and management of heart failure. We will discuss the new 
recommendation from ESC and AHA guideline for heart failure. 
 
Introduction  
On the 2012 guideline, heart failure 
was classified into 2 categories based on 
fraction ejection, heart failure with reduced 
ejection fraction (HFrEF) for ejection 
fractions below 40% and heart failure with 
preserved ejection fraction (HFpEF) for 
ejection fractions above 50%. This 
classification can also illustrate the 
pathophysiological differences between 
HFrEF and HFpEF wherein HFrEF 
involves volume overload while the 
pathophysiology of HFpEF involves 
pressure overload. However, the 2012 
guidelines still leave the gray area for 
ejection of 40-49% fraction. So that in the 
latest guideline, the ejection fraction of 40-
49% is grouped into a new classification, 
namely heart failure with mid-range 
ejection fraction (HFmrEF). This 
classification is expected to encourage 
more research in this population because 
until now only in the HFrEF group has it 
been proven that administration of heart 
failure therapy can reduce mortality and 
morbidity.1 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Algorithm for diagnosing heart failure in non-acute conditions1 
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The latest guidelines also add an 
algorithm to enforce the diagnosis of heart 
failure in a non-acute setting (Figure 1). 
The algorithm starts with assessing the 
probability of a diagnosis of heart failure 
by looking at the patient's clinical history, 
physical examination and ECG. If there is 
no abnormality in one of the clinical points, 
it is unlikely that the patient will have heart 
failure so another diagnosis is needed. 
However, even if only 1 abnormality is 
found, an NT pro BNP examination is 
necessary. An echocardiographic 
examination is performed if there is an 
increase in levels of NT pro BNP.1 
The most important point added to 
the latest guideline is management of 
heart failure, especially HFrEF. At the 
latest guildeline of ESC and AHA, new 
therapies for reduced EF heart failure 
management algorithms are added, 
namely ARNI therapy (angiotensin-renin 
and neprylisin inhibitors) and ivabradine. 
ARNI therapy that has been tested is a 
combination of sacubitrile-valsartan, and is 
known to work by inhibiting neprilysin, 
which is the degradation of natriuretic 
peptides. Sacubitril-valsartan is 
recommended as an ACE inhibitor 
replacement therapy in symptomatic 
HFrEF patients even with optimal 
treatment of ACE inhibitors, beta blockers 
and mineral corticoid-receptor antagonists, 
and from several studies proven to reduce 
the risk of hospitalization and death. 
However, ARNI should not be given in 
conjunction with an ACE inhibitor and is 
recommended starting 36 hours after the 
last dose of ACE inhibitor. ARNI therapy is 
also not recommended for patients with a 
history of angioedema.1,2 
From the latest clinical trial, 
ivabradine therapy is known to reduce 
hospitalization in heart failure patients with 
reduced EF who are still symptomatic with 
optimal therapy (ACE inhibitors, beta 
blockers). So that in the latest guideline, it 
is recommended to be given to heart 
failure patients with reduced EF, who are 
still symptomatic even with optimal 
therapy, with a sinus rhythm ECG and a 
pulse of ≥70 times per minute.1,3,4 
 
Table 1. Recent recommendations for HFrEF management according to ESC 
Guidelines1 
Recommendation Class Level of 
evidence 
Sacubitril / valsartan is recommended as an ACE inhibitor 
replacement therapy in HFrEF patients who still have 
symptoms even with optimal ACE inhibitor, beta blockers 
and mineralcorticoid antagonist therapy 
I B 
Ivabradine can be considered for administration to 
patients with HFrEF, has a sinus rhythm with a resting 
pulse ≥70 times per minute, who still has symptoms even 
with optimal beta blocker, ACE inhibitors, and 
mineralcorticoid antagonist therapy 
IIa B 
Ivabradine can be considered for administration to 
patients with HFrEF, has a sinus rhythm with a resting 
pulse ≥70 times per minute, who has ACE inhibitor and 
mineralcorticoid antagonist therapy but has 
contraindications for administration of beta blockers or 
cannot tolerate administration of beta blockers. 
IIa C 
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Table 2. Recent recommendations for HFrEF management according to the 
AHA Guideline2 
Recommendation Class 
HFrEF patients who can tolerate ACE inhibitors or ARBs but are still 
symptomatic with NYHA II-III, replacement of ACE inhibitors or ARBs with 
ARNI is recommended to reduce morbidity and mortality 
I 
ARNI should not be given together with ACE inhibitors or within 36 hours 
after the last dose of ACE inhibitor 
III 
ARNI should not be given to patients with a history of angioedema III 
Ivabradine can be useful to reduce hospitalization due to heart failure if 
given to symptomatic HFrEF patients (NYHA II-III) despite optimal heart 
failure therapy, who sinus rhythms with a pulse rate of ≥70 times per minute 
at rest 
IIa 
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